Loading...
ALLK logo

Allakos Inc.NasdaqGS:ALLK Stock Report

Market Cap US$29.7m
Share Price
n/a
US$0.35
n/aintrinsic discount
1Y-77.1%
7D0.2%
Portfolio Value
​
View

Allakos Inc.

NasdaqGS:ALLK Stock Report

Market Cap: US$29.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Allakos (ALLK) Stock Overview

A clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. More details

ALLK fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Earnings have grown 1.2% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($30M)

+ 1 more risk

ALLK Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Allakos Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Allakos
Historical stock prices
Current Share PriceUS$0.33
52 Week HighUS$1.56
52 Week LowUS$0.22
Beta0.14
1 Month Change1.89%
3 Month Change5.24%
1 Year Change-77.15%
3 Year Change-89.03%
5 Year Change-99.57%
Change since IPO-98.95%

Recent News & Updates

Analysis Article • Mar 27

Here's Why We're A Bit Worried About Allakos' (NASDAQ:ALLK) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Recent updates

Analysis Article • Mar 27

Here's Why We're A Bit Worried About Allakos' (NASDAQ:ALLK) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 07

Allakos Runs Up Into A Near-Term Catalyst

Summary Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006 demonstrates that the drug may not require frequent dosing, which may be important given potential competition from oral remibrutinib. Upcoming Q1'25 data from a randomized, double-blind, placebo-controlled trial of IV AK006 in over 30 CSU patients is a near-term catalyst. Read the full article on Seeking Alpha
Analysis Article • Aug 27

We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • May 05

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Dec 01

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Aug 03

Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Apr 20

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 04

Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

Key Insights Allakos' estimated fair value is US$6.2 based on 2 Stage Free Cash Flow to Equity Current share price of...
Seeking Alpha • Oct 18

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Summary Results from the phase 2b study, using lirentelimab for the treatment of patients with chronic spontaneous urticaria, are expected in the 2nd half of 2023. Xolair naive CSU cohort of 13 patients started with an average UAS7 score of 18.5 points at baseline and at week 22 dropped down to 4.6 points. Results from the phase 2b study, using lirentelimab for the treatment of patients with atopic dermatitis, are expected in the 2nd half of 2023. Allakos had $212.4 million in cash as of June 30, 2022, but just recently raised $150 million in a public offering. I believe it should have sufficient cash to fund its operations until late 2023.
Seeking Alpha • Sep 19

Allakos prices ~$150M underwritten offering

Biotechnology company Allakos (NASDAQ:ALLK) is pricing an underwritten offering of 29.9M shares at $5.02 per share. The expected gross proceeds from the offering, estimated to close on or about Sep. 21, will be ~$150M. Logos Capital, Alta Partners, Braidwell, BVF Partners, Commodore Capital, Deep Track Capital, Frazier Life Sciences, New Enterprise Associates (NEA), RTW Investments, Surveyor Capital, TCGX and Vivo Capital have agreed to purchase shares in the offering. Allakos will sell all the shares in the offering. The offering is subject to the satisfaction of customary closing conditions. ALLK shares were trading -2.62% pre-market. Source: Press Release
Seeking Alpha • Sep 09

Allakos falls as lead asset offers mixed results in late-stage trial

The shares of clinical-stage biotech Allakos (NASDAQ:ALLK) dropped ~12% in the pre-market Friday after the company announced mixed results from its Phase 3 trial for lead asset lirentelimab in eosinophilic duodenitis ((EoD)), an inflammatory condition in the gastrointestinal tract. The randomized, double-blind study involved 93 biopsy-confirmed eosinophilic duodenitis patients who received monthly lirentelimab or placebo. The trial met its histologic co-primary endpoint but failed to achieve the statistical significance on the patient-reported symptomatic co-primary endpoint for the intent to treat (ITT) population, ALLK said. The company added that similar results were seen in a prespecified subpopulation that excluded certain patients whose conditions could cofound patient reported symptomatic endpoint. ALLK said it is not planning to conduct additional studies on eosinophilic gastrointestinal diseases as of now. Read more on the upcoming milestones for the company as announced with its Q2 2022 results.
Analysis Article • Aug 06

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Apr 22

Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Dec 23

Allakos: Sad End To A Promising Asset

Lirentelimab's phase 3 failures are spectacular considering the excellent phase 2 data. No one has yet figured out how this went down. However, from every angle, the future of the company looks bleak.
Analysis Article • Dec 01

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Aug 16

We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 06

Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

ALLK is targeting a large and untapped market. It has upcoming phase 3 data announcement later this year. The stock is trading near 52-week lows.
Analysis Article • May 02

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 10

Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?

We wouldn't blame Allakos Inc. ( NASDAQ:ALLK ) shareholders if they were a little worried about the fact that Robert...
Analysis Article • Jan 28

Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Analysis Article • Dec 07

We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

ALLKUS BiotechsUS Market
7D0.2%-1.8%-0.3%
1Y-77.1%32.7%24.1%

Return vs Industry: ALLK underperformed the US Biotechs industry which returned -18.2% over the past year.

Return vs Market: ALLK underperformed the US Market which returned 10.6% over the past year.

Price Volatility

Is ALLK's price volatile compared to industry and market?
ALLK volatility
ALLK Average Weekly Movement14.5%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: ALLK's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ALLK's weekly volatility has decreased from 20% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2012131Robert Alexanderwww.allakos.com

Allakos Inc., a clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Allakos Inc. Fundamentals Summary

How do Allakos's earnings and revenue compare to its market cap?
ALLK fundamental statistics
Market capUS$29.74m
Earnings (TTM)-US$70.85m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.4x
P/E Ratio

Is ALLK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALLK income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$70.85m
Earnings-US$70.85m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.78
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ALLK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 13:20
End of Day Share Price 2025/05/14 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allakos Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Jason ZemanskyBofA Global Research
Jennifer KimCantor Fitzgerald & Co.